Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_1
7
88%
Ph phase_2
1
13%

Phase Distribution

7

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
7(87.5%)
Phase 2Efficacy & side effects
1(12.5%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 17 (87.5%)
Phase 21 (12.5%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completedphase_1

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

NCT02658825
completedphase_1

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

NCT02888327
completedphase_2

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT02532283
completedphase_1

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

NCT02860806
completedphase_1

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

NCT02448004
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT02658825Phase 1

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Completed
NCT02888327Phase 1

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Completed
NCT02532283Phase 2

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

Completed
NCT02860806Phase 1

Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults

Completed
NCT02448004Phase 1

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Completed
NCT03023852Phase 1

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants

Completed
NCT02652650Phase 1

A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone

Completed
NCT02595268Phase 1

A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8